Multicenter Trial Management Unit Expands the Scope of Research at Yale
In the past, Yale investigators who led multicenter trials had to put together ad hoc study teams, relying on unconnected siloed services to carry out their research. At the end of these trials, these teams, which had compiled so much experience and knowledge, disbanded and their knowledge was lost. This system was inefficient and put Yale at a disadvantage when competing with other institutions for grants for multicenter studies.
Yale Cancer Center Awards for Clinical Excellence presented during annual Conclave
Debra Brandt, D.O. and Kevin Kim, M.D. were each honored with the Yale Cancer Center (YCC) Award for Clinical Excellence at YCC’s annual Conclave on Monday, January 13. The night celebrated the accomplishments of goals set for 2019 and honored faculty and staff with clinical and research prizes.
Huntington and Parker receive new appointments at Smilow Cancer Hospital
Scott Huntington, M.D., M.P.H., assistant professor of Medicine (Hematology), has been named Medical Director for the Hematology Outpatient Program at Smilow Cancer Hospital and Terri Parker, M.D., assistant Professor of Medicine (Hematology), has been appointed the inaugural Assistant Medical Director for the Smilow Cancer Hospital Care Center in North Haven, which includes multiple myeloma and benign hematology care.
Sanft named Chief Patient Experience Officer at Smilow Cancer Hospital
Tara Sanft, M.D., associate professor of Medicine (Medical Oncology) and Director of the Smilow Cancer Hospital (SCH) Survivorship Clinic, has been appointed the inaugural Chief Patient Experience Officer at Yale Cancer Center (YCC) and SCH at Yale New Haven Hospital.
Yale Cancer Center launches Center for Community Engagement and Health Equity
Yale Cancer Center (YCC) announces the launch of the Center for Community Engagement and Health Equity (CEHE). Building on YCC’s longstanding commitment to high-quality, expert, and patient-centered cancer care, screening, and prevention across the state of Connecticut, the new Center is dedicated to ensuring cancer health equity and improving outcomes with an emphasis on traditionally underserved neighborhoods.
When Cells Cycle Fast, Cancer Gets a Jumpstart
The progression of cancer has been studied extensively, and the key steps in this journey have been well mapped, at least in some solid tumors: Lesions to genes that confer risk of cancer accumulate and alter normal cell behaviors, giving rise, scientists believe, to early stage cancer cells that eventually swamp normal cells and become deadly.
Yale Cancer Center Researchers Investigate Inducing “Synthetic Lethality” in Two Blood and Bone Cancers
In a clinical trial led by Yale Cancer Center (YCC) and Smilow Cancer Hospital, researchers aim to exploit DNA mutations in the treatment of two blood and bone marrow cancers, a different tacit than the more traditional approach of blunting or switching off genetic mutations linked to cancer.
Yale Cancer Center study shows Artificial Intelligence can help radiologists find microscopic evidence of advancing head and neck cancer
New findings by researchers at Yale Cancer Center (YCC) show deep learning algorithms can outperforms radiologists in finding microscopic infiltrations of head and neck cancer in lymph nodes.
Yale Cancer Center study suggests new approaches needed to manage ibrutinib-related toxicities in CLL patients
New findings by Yale Cancer Center (YCC) and Smilow Cancer Hospital researchers show that as the use of the drug ibrutinib climbs in patients with chronic lymphocytic leukemia (CLL), so do the rates of patients who stop taking the drug.
Yale Cancer Center researchers show promising new treatment for patients with myelodysplastic syndromes
A new study by Yale Cancer Center (YCC) and Smilow Cancer Hospital researchers suggests that the drug venetoclax aids therapy for relapsed/refractory myelodysplastic syndromes, especially when paired with azacytidine.
Yale Cancer Center Study Shows Checkpoint Inhibitor Prolongs Survival in Patients With Certain Head and Neck Cancers
The checkpoint inhibitor pembrolizumab (Keytruda) offers patients with advanced head and neck cancers longer survival time, according to a new global study led by Yale Cancer Center (YCC).
Smilow Cancer Hospital celebrates 10th anniversary
Smilow Cancer Hospital at Yale New Haven celebrates 10 years since it opened its doors to a new state-of-the-art inpatient and outpatient 500,000-square-foot cancer care facility. Since that day in October 2009, Smilow Cancer Hospital and Yale Cancer Center have risen to the top echelon as one of the nation’s comprehensive cancer research and care facilities, providing advanced care to patients and families and pioneering cancer research.